# Stereotaxis, Inc.: overview STXS · NYSE · CIK 1289340 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/stxs.md) · [Financials](/companies/stxs/financials.md) · [Filings](/companies/stxs/filings.md) · [Insiders](/companies/stxs/insiders.md) Latest reported revenue: [$7.7m](/filings/0001493152-26-037357.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-037357). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [9,196](/filings/0001493152-25-021881.md) | [6,340 d](/filings/0001493152-26-009881.md) | [7,472](/filings/0001493152-26-022697.md) | [8,798](/filings/0001493152-26-037357.md) | [7,464](/filings/0001493152-25-021881.md) | [8,642 d](/filings/0001493152-26-009881.md) | [6,291](/filings/0001493152-26-022697.md) | [7,670](/filings/0001493152-26-037357.md) | | Gross margin | % | [44.6%](/filings/0001493152-25-021881.md) | [50.7% d](/filings/0001493152-26-009881.md) | [54.4%](/filings/0001493152-26-022697.md) | [52.0%](/filings/0001493152-26-037357.md) | [54.9%](/filings/0001493152-25-021881.md) | [50.1% d](/filings/0001493152-26-009881.md) | [60.3%](/filings/0001493152-26-022697.md) | [58.5%](/filings/0001493152-26-037357.md) | | Operating margin | % | [(69.0%)](/filings/0001493152-25-021881.md) | [(120.3%) d](/filings/0001493152-26-009881.md) | [(79.3%)](/filings/0001493152-26-022697.md) | [(45.2%)](/filings/0001493152-26-037357.md) | [(87.8%)](/filings/0001493152-25-021881.md) | [(65.4%) d](/filings/0001493152-26-009881.md) | [(95.1%)](/filings/0001493152-26-022697.md) | [(59.6%)](/filings/0001493152-26-037357.md) | | Net margin | % | [(67.3%)](/filings/0001493152-25-021881.md) | [(118.5%) d](/filings/0001493152-26-009881.md) | [(77.9%)](/filings/0001493152-26-022697.md) | [(43.5%)](/filings/0001493152-26-037357.md) | [(86.6%)](/filings/0001493152-25-021881.md) | [(64.0%) d](/filings/0001493152-26-009881.md) | [(93.2%)](/filings/0001493152-26-022697.md) | [(58.3%)](/filings/0001493152-26-037357.md) | | Diluted EPS | $ per share | [(0.08)](/filings/0001493152-25-021881.md) | not reported | [(0.07)](/filings/0001493152-26-022697.md) | [(0.05)](/filings/0001493152-26-037357.md) | [(0.07)](/filings/0001493152-25-021881.md) | not reported | [(0.06)](/filings/0001493152-26-022697.md) | [(0.05)](/filings/0001493152-26-037357.md) | | Free cash flow | $k | [(4,339) d](/filings/0001493152-25-021881.md) | [1,264 d](/filings/0001493152-26-009881.md) | not reported | not reported | [(4,204) d](/filings/0001493152-25-021881.md) | [(4,039) d](/filings/0001493152-26-009881.md) | [(3,521)](/filings/0001493152-26-022697.md) | [(3,739) d](/filings/0001493152-26-037357.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [35.0](/filings/0001493152-23-007106.md) | [28.1](/filings/0001493152-24-009371.md) | [26.8](/filings/0001493152-25-010352.md) | [26.9](/filings/0001493152-26-009881.md) | [32.4](/filings/0001493152-26-009881.md) | | Gross margin | % | [66.3%](/filings/0001493152-23-007106.md) | [65.6%](/filings/0001493152-24-009371.md) | [55.5%](/filings/0001493152-25-010352.md) | [54.2%](/filings/0001493152-26-009881.md) | [52.7%](/filings/0001493152-26-009881.md) | | Operating margin | % | [(36.8%)](/filings/0001493152-23-007106.md) | [(66.7%)](/filings/0001493152-24-009371.md) | [(81.6%)](/filings/0001493152-25-010352.md) | [(91.9%)](/filings/0001493152-26-009881.md) | [(68.3%)](/filings/0001493152-26-009881.md) | | Net margin | % | [(30.6%)](/filings/0001493152-23-007106.md) | [(65.0%)](/filings/0001493152-24-009371.md) | [(77.4%)](/filings/0001493152-25-010352.md) | [(89.3%)](/filings/0001493152-26-009881.md) | [(66.8%)](/filings/0001493152-26-009881.md) | | Diluted EPS | $ per share | [(0.16)](/filings/0001493152-23-007106.md) | [(0.26)](/filings/0001493152-24-009371.md) | [(0.27)](/filings/0001493152-25-010352.md) | [(0.30)](/filings/0001493152-26-009881.md) | [(0.25)](/filings/0001493152-26-009881.md) | | Free cash flow | $m | [(4.3)](/filings/0001493152-23-007106.md) | [(10.8)](/filings/0001493152-24-009371.md) | [(9.5)](/filings/0001493152-25-010352.md) | [(8.5)](/filings/0001493152-26-009881.md) | [(13.8)](/filings/0001493152-26-009881.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/stxs/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [DAFNA Capital Management LLC](/funds/1389933.md) | 2026-06-30 | $23.5m | 13,680,554 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $7.6m | 4,396,835 | | Added +440,592 | | [Lagoda Investment Management, L.P.](/funds/1632108.md) | 2026-06-30 | $7.1m | 4,122,600 | | Reduced −227,800 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.2m | 3,044,820 | | Added +46,776 | | [Arbiter Partners Capital Management LLC](/funds/1513193.md) | 2026-06-30 | $5.0m | 2,883,856 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $3.3m | 1,895,243 | | Added +219,835 | | [ESSEX INVESTMENT MANAGEMENT CO LLC](/funds/201772.md) | 2026-06-30 | $2.6m | 1,521,966 | | Reduced −68,135 | | [Archon Capital Management LLC](/funds/1398825.md) | 2026-06-30 | $2.1m | 1,226,044 | | Unchanged | | [Warberg Asset Management LLC](/funds/1597506.md) | 2026-06-30 | $1.9m | 1,108,889 | | Added +14,766 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.6m | 916,780 | | Reduced −40,988 | ## Recent filings [All 1,159 filings](/companies/stxs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-12 | 16:13 ET | [10-Q](/filings/0001493152-26-037357.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037357 | | 2026-08-11 | 16:05 ET | [8-K](/filings/0001493152-26-037113.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-037113 | | 2026-07-16 | 17:37 ET | [8-K](/filings/0001493152-26-033405.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-033405 | | 2026-07-09 | 08:13 ET | [8-K](/filings/0001493152-26-032598.md) | 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-032598 | | 2026-05-15 | 15:31 ET | [8-K](/filings/0001493152-26-023654.md) | 5.07 Shareholder vote results | 0001493152-26-023654 | | 2026-05-13 | 15:42 ET | [10-Q](/filings/0001493152-26-022697.md) | Quarterly report, period 2026-03-31 | 0001493152-26-022697 | | 2026-05-12 | 16:10 ET | [8-K](/filings/0001493152-26-022488.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001493152-26-022488 | | 2026-04-15 | 07:15 ET | [8-K](/filings/0001493152-26-016685.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-016685 | | 2026-04-03 | 17:00 ET | [10-K/A](/filings/0001493152-26-015172.md) | Annual report, amended, period 2025-12-31 | 0001493152-26-015172 | | 2026-04-03 | 06:04 ET | [DEF 14A](/filings/0001493152-26-015027.md) | Proxy statement, period 2026-04-03 | 0001493152-26-015027 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-009881.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/6133c4de-70a3-4e16-b51b-01360b5e0076) ## About the filer - CIK: 1289340 - Tickers: STXS - Exchange: NYSE - SIC code: 3845 Electromedical & Electrotherapeutic Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.